Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study

Isatuximab, an anti‐CD38 monoclonal antibody, targets cells that strongly express CD38 including malignant plasma cells. This open‐label, single‐arm, multicenter, phase 1/2 trial investigated the tolerability/safety and efficacy of isatuximab monotherapy in Japanese patients with heavily pretreated,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sunami, Kazutaka, Suzuki, Kenshi, Ri, Masaki, Matsumoto, Morio, Shimazaki, Chihiro, Asaoku, Hideki, Shibayama, Hirohiko, Ishizawa, Kenichi, Takamatsu, Hiroyuki, Ikeda, Takashi, Maruyama, Dai, Kaneko, Hitomi, Uchiyama, Michihiro, Kiguchi, Toru, Iyama, Satoshi, Murakami, Hirokazu, Takahashi, Keishiro, Tada, Keisuke, Macé, Sandrine, Guillemin‐Paveau, Hélène, Iida, Shinsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734004/
https://www.ncbi.nlm.nih.gov/pubmed/32975869
http://dx.doi.org/10.1111/cas.14657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734004/
https://www.ncbi.nlm.nih.gov/pubmed/32975869
http://dx.doi.org/10.1111/cas.14657

Ejemplares similares